LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer

Research output: Contribution to journalArticle

Standard

LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. / Thomasson, Marcus; Wang, Baofeng; Hammarsten, Peter; Dahlman, Anna K; Persson, Jenny L; Josefsson, Andreas; Stattin, Par; Granfors, Torvald; Egevad, Lars; Henriksson, Roger; Bergh, Anders; Hedman, Hakan.

In: International Journal of Cancer, Vol. 128, No. 12, 2011, p. 2843-2852.

Research output: Contribution to journalArticle

Harvard

Thomasson, M, Wang, B, Hammarsten, P, Dahlman, AK, Persson, JL, Josefsson, A, Stattin, P, Granfors, T, Egevad, L, Henriksson, R, Bergh, A & Hedman, H 2011, 'LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer', International Journal of Cancer, vol. 128, no. 12, pp. 2843-2852. https://doi.org/10.1002/ijc.25820

APA

Thomasson, M., Wang, B., Hammarsten, P., Dahlman, A. K., Persson, J. L., Josefsson, A., ... Hedman, H. (2011). LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. International Journal of Cancer, 128(12), 2843-2852. https://doi.org/10.1002/ijc.25820

CBE

Thomasson M, Wang B, Hammarsten P, Dahlman AK, Persson JL, Josefsson A, Stattin P, Granfors T, Egevad L, Henriksson R, Bergh A, Hedman H. 2011. LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. International Journal of Cancer. 128(12):2843-2852. https://doi.org/10.1002/ijc.25820

MLA

Vancouver

Author

Thomasson, Marcus ; Wang, Baofeng ; Hammarsten, Peter ; Dahlman, Anna K ; Persson, Jenny L ; Josefsson, Andreas ; Stattin, Par ; Granfors, Torvald ; Egevad, Lars ; Henriksson, Roger ; Bergh, Anders ; Hedman, Hakan. / LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. In: International Journal of Cancer. 2011 ; Vol. 128, No. 12. pp. 2843-2852.

RIS

TY - JOUR

T1 - LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer

AU - Thomasson, Marcus

AU - Wang, Baofeng

AU - Hammarsten, Peter

AU - Dahlman, Anna K

AU - Persson, Jenny L

AU - Josefsson, Andreas

AU - Stattin, Par

AU - Granfors, Torvald

AU - Egevad, Lars

AU - Henriksson, Roger

AU - Bergh, Anders

AU - Hedman, Hakan

PY - 2011

Y1 - 2011

N2 - The course of prostate cancer varies greatly, and additional prognostic markers are needed. Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) is an endogenous inhibitor of growth factor signaling and a proposed tumor suppressor. Publicly available gene expression datasets indicate that LRIG1 may be overexpressed in prostate cancer. In our study, the expression of LRIG1 protein in prostate cancer was evaluated for the first time. Immunohistochemistry was performed on tissue microarrays from two different patient series: 355 Swedish patients diagnosed by transurethral resection and 293 American patients who underwent radical prostatectomy. In the Swedish series, high expression of LRIG1 correlated with Gleason score, T-stage, tumor cell proliferation, vascular density and epidermal growth factor receptor (EGFR) phosphorylation. Among the 256 Swedish patients, followed by watchful waiting, high LRIG1 expression was significantly associated with short overall and prostate cancer-specific survival. In contrast, in the US series, high LRIG1 expression was significantly associated with long overall survival. In vitro cell experiments showed that LRIG1 was induced by androgen stimulation, and its expression inhibited prostate cancer cell proliferation. Thus, LRIG1 expression was an independent marker for poor survival in the untreated patient series, perhaps as a secondary marker of androgen receptor and/or EGFR activation. On the contrary, LRIG1 was a marker for good prognosis after prostatectomy, which might be due to its growth inhibiting properties. We propose that LRIG1 is an important determinant of prostate cancer growth, and the implications of its expression on patient outcome depend on the clinical and biological circumstances.

AB - The course of prostate cancer varies greatly, and additional prognostic markers are needed. Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) is an endogenous inhibitor of growth factor signaling and a proposed tumor suppressor. Publicly available gene expression datasets indicate that LRIG1 may be overexpressed in prostate cancer. In our study, the expression of LRIG1 protein in prostate cancer was evaluated for the first time. Immunohistochemistry was performed on tissue microarrays from two different patient series: 355 Swedish patients diagnosed by transurethral resection and 293 American patients who underwent radical prostatectomy. In the Swedish series, high expression of LRIG1 correlated with Gleason score, T-stage, tumor cell proliferation, vascular density and epidermal growth factor receptor (EGFR) phosphorylation. Among the 256 Swedish patients, followed by watchful waiting, high LRIG1 expression was significantly associated with short overall and prostate cancer-specific survival. In contrast, in the US series, high LRIG1 expression was significantly associated with long overall survival. In vitro cell experiments showed that LRIG1 was induced by androgen stimulation, and its expression inhibited prostate cancer cell proliferation. Thus, LRIG1 expression was an independent marker for poor survival in the untreated patient series, perhaps as a secondary marker of androgen receptor and/or EGFR activation. On the contrary, LRIG1 was a marker for good prognosis after prostatectomy, which might be due to its growth inhibiting properties. We propose that LRIG1 is an important determinant of prostate cancer growth, and the implications of its expression on patient outcome depend on the clinical and biological circumstances.

KW - LRIG1

KW - prostate cancer

KW - survival

U2 - 10.1002/ijc.25820

DO - 10.1002/ijc.25820

M3 - Article

VL - 128

SP - 2843

EP - 2852

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 12

ER -